TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentReactivation of telomerase in cancerTERT promoter mutations in thyroid cancerCIViC databaseClinical and biological determinants of melanoma progression: Should all be considered for clinical management?Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancersSDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanomaAssociation of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERTAssociation Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis.High nevus counts confer a favorable prognosis in melanoma patients.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.Revisiting determinants of prognosis in cutaneous melanoma.Analysis of SDHD promoter mutations in various types of melanomaSF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas.Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapyBRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patientsIn the Wnt-er of life: Wnt signalling in melanoma and ageing.Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma.KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.Genetics of melanoma progression: the rise and fall of cell senescence.Understanding TERT Promoter Mutations: A Common Path to Immortality.Differential diagnosis of Spitzoid melanocytic neoplasms.Altered TERT promoter and other genomic regulatory elements: occurrence and impact.Contemporary and potential future molecular diagnosis of melanoma.Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.Biomarkers in melanoma.TERT promoter mutations in melanoma survival.Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.
P2860
Q26738705-D1ABE68D-5AB3-406B-8E63-0B8B662FCD18Q26739925-33CED29F-FFAC-42C6-94ED-A767754DD4A1Q26740631-F5A87DCC-CD77-4CBB-9AA7-FC7524BE04FCQ26769014-00E820EF-7F37-4C93-A3EF-8D5006AAB75CQ26770808-99CCB0C1-4EDB-485D-8CBC-F30F4D7B31B0Q27612411-121B87FC-96A8-4209-B1A2-9317C02C3E8DQ30252150-2CE0806D-5FF5-4DFB-8436-6AB697BD20F7Q30459839-C4E84FC2-1428-4AE8-B863-E13C86DE53FAQ33853615-C42F7867-07ED-40EE-A95B-55D684BECE74Q35441872-9B36E2D4-A5E4-4C57-8A2B-8038FF020434Q35711083-6284896B-C712-467D-9904-B4813258A520Q35751775-D09B84E3-4883-4BFE-B5C8-92C7DB463933Q35801085-AC05658F-7F73-4265-9BCE-982147164D7DQ35849079-253D7C55-E53C-4456-A3E7-DA4AD8529565Q35855182-CA1723FB-60C8-476C-9F6D-2DCED991B9F7Q35901458-124B5D7D-5FEA-436D-A467-003618880B88Q36064844-538A0A5E-E171-472E-9D16-58D5DF34DF29Q36338825-B6167985-99DA-4316-BA25-6BCE5246739BQ36413313-F0210A89-4241-4ED2-B837-40F6FFF505BBQ36466870-C73A0985-25B1-4985-9209-89A455D8CCBAQ36755569-93A04BF1-3153-49EA-AE1D-C6A9E3A9640DQ37109755-80E5AABF-97DC-432A-A67A-EA0FC906783DQ37457229-CA6B98F9-2A67-464D-9D16-F9EFC2B96FB7Q37514988-B0970621-F365-437A-BD93-D299FA2C97FFQ37596836-E5C5755B-90DA-4CBE-B14C-08B981EE477EQ37687028-767592D7-3B7C-490B-864B-4F39FEB5E589Q37738007-0A04C7B4-7801-40D5-9E7C-E228CA5F7B1AQ38372948-F593FF89-1F76-455C-8E4E-4E24334D27A1Q38589518-76A6864C-955F-4BC0-9CC2-86B763C2BE52Q38760235-B0121952-FD0B-41D8-AAFC-B22C78D76772Q38833186-632F1E86-3318-4CDF-8817-F5F9911EBA91Q38838144-326A5077-58A6-48A4-827F-2D190945A089Q38847989-CB53A84F-D639-4458-A7B6-5C2ED70A5DC0Q38852335-11F787AC-5C18-478F-B975-037DF46B6A98Q38911167-3053A3D7-E372-420C-8E3E-FB03C4B23F5FQ39998496-3BABDEE2-6B4D-4DC0-806E-5088E5DFBCDCQ40199208-3F9D5B92-8BEF-41B8-AEB0-F9E99520DF1CQ40418885-10C026A1-7A59-4AD6-B4AA-DC49A5DC196EQ40857012-D706B9C1-363D-4B4D-BE68-E390EF9272A1Q41642490-CD29A24F-3E6C-4F70-9FD9-F31111FD1AFA
P2860
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@ast
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@en
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@nl
type
label
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@ast
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@en
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@nl
altLabel
TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
@en
prefLabel
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@ast
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@en
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@nl
P2093
P2860
P50
P3181
P356
P1476
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
@en
P2093
Bastian Schilling
Celia Badenas
Elisabeth Livingstone
Inga Möller
Joan Anton Puig-Butille
Lisa Zimmer
Marion Schwamborn
Tobias Schimming
Uwe Hillen
P2860
P304
dju246-dju246
P3181
P356
10.1093/JNCI/DJU246
P407
P50
P577
2014-09-01T00:00:00Z